OVERVIEW
OF THE PHARMACEUTICAL MARKET IN NORWAY
The macroenvironment for the Norwegian
pharmaceutical industry is improving. Politically, the centre-left
coalition is expected to hold together at least until the general election in
September 2013, but the risk of the coalition breaking up has grown.
Economically, the recession was far less pronounced in Norway than in most
other European countries and economic recovery is now strengthening. Legally,
laws on intellectual property and patent provision are in line with WTO/TRIPS
regulations. However, Norway remains on the USTR’s Watch List in 2011 for
concerns over patent protection. Demographically, the population is ageing,
increasing demand for pharmaceuticals in the near term.
The introduction of international reference pricing
has had a moderating effect on Norwegian pharmaceutical price levels, and a
step-price system for off-patent drugs has ensured that prices for all generics
have fallen. Important steps towards cost-containment have also been taken for
reimbursable pharmaceuticals, including the use of a first-choice system. A
report by the Business Research Foundation (SNF) has shown that Norwegian
pharmaceutical prices are among the lowest in Western Europe. Therefore, market
growth is a result of increased consumption, largely due to the ageing
population and the introduction of new drugs on the market. Norway is receptive
to new drugs, as long as they are cost-effective and have proven therapeutic
benefits.
Inquire
For Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=81367
Although
Norway is not part of the European Union, the process for pharmaceutical
registration has been aligned to EU regulations. The regulatory reforms made
the centralised procedure mandatory for all new active substances, and all
drugs in a number of drug categories, including all biotech products. In May
2011, PCI Biotech reported that it had been awarded a BIA grant from the
Research Council of Norway for the project “immunological effects of
photochemical internalisation – local treatment of cancer with metastasis”. The
project was initiated in the third quarter of 2011, and will run for three
years.
Buy a Report Copy @ http://www.rnrmarketresearch.com/contacts/purchase?rname=81367
For
more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441
